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Application of SeDeM expert systems in preformulation studies 
of pediatric ibuprofen ODT tablets
Pediatric, ibuprofen containing orodispersible tablets (ODTs) 
were prepared using the SeDeM expert system methodology. 
In order to facilitate formulation, directly compressible ibu-
profen was employed (Ibuprofen DC 85™) and character-
ized using its SeDeM profile. The mannitol based superdis-
integrant Ludiflash® was characterized by the SeDeM-ODT 
expert system, which also allowed calculation of the opti-
mal excipient concentration in order to obtain suitable tablet 
hardness and disintegration time. After adding a sweetener 
and a standard combination of lubricants, the optimized 
formulation was directly compressed into tablets and evalu-
ated in terms of tablet hardness, friability, disintegration 
time and dissolution profile. The SeDeM method was ap-
plied to determine the amount of corrective excipient (Ludi-
flash®) required for the compression of Ibuprofen DC 85™ 
in order to achieve suitable ODTs. Adequate tablet hardness, 
disintegration time, friability and dissolution profiles were 
found during tablet evaluation.
Keywords: Ibuprofen DC 85™, Ludiflash®, orodispersible, 
SeDeM
Pediatric medication is specific from the point of view of pharmaceutical forms and 
in terms of active substances for this age group. In addition to specific pediatric therapy 
formulations such as suppositories, oral suspensions and soft capsules, new forms have 
been also described recently. ODTs are among these new forms. The European Pharmaco-
poeia (Ph. Eur.) defines ODTs as uncoated tablets intended to be placed in the mouth, 
where they disperse rapidly before being swallowed (1). In order to achieve rapid disinte-
gration, the tablets need to be porous and possess adequate mechanic strength to ensure 
stability during storage or transport (2).
In the past decade, attention was focused on the development of ODTs by trying dif-
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turers started marketing a number of so-called superdisintegrants that can be success-
fully used to achieve ODTs. On the other hand, many known techniques for preparing 
such pharmaceutical forms, such as lyophilization, freeze-drying, molding and direct 
com pression techniques were also described (2, 3). Direct compression is a frequently used 
method to produce ODTs because it uses high efficiency tablet presses and a great variety 
of excipients. In this case, the most important step of ODT formulation consists of super-
disintegrant selection and determination of its concentration (2). 
In our particular case, Ludiflash® (a product developed by BASF) has been chosen as 
a superdisintegrant. One purpose of this study was to determine the amount of this ex-
cipient and the composition of a powder mixture suitable for direct compression in order 
to obtain ODTs.
Another important factor to consider is the suitability of the active pharmaceutical 
ingredient for direct compression. The SeDeM method has been applied to predict the 
suitability of the different excipients. Suñé et al. (4) described the preformulation method-
ology named the SeDeM Diagram expert system to characterize the active substances, 
excipients and powder blends in order to find if they have appropriate physicochemical 
properties to be directly compressed. Applying the method and using the formula pro-
posed by Suñé et al. (5), it is possible to detect excipient properties that need improvement 
in order to enable direct compression as the method of manufacture.
Recent studies used SeDeM Diagrams to characterize a large number of disintegrants 
in order to verify their suitability for preparing ODTs by direct compression (6). It has also 
been shown that two newly introduced parameters, Index of Good Compressibility (IGC) 
and Index of Good Compressibility Bucodispersibility (IGCB), make it possible the calcu-
late the quantity of superdisintegrant that enables both direct compressibility and suitable 
disintegration times (less than 3 minutes) (7, 8). Thus, SeDeM and SeDeM-ODT expert 
systems can save time and considerable financial resources in both preformulation and 
formulation phases (9, 10). 
The aim of this study is the development of pediatric ODTs, prepared by direct com-
pression, containing ibuprofen as an active substance. In 2011, Tayebi et al. described the 
formulation of 100 mg ibuprofen ODTs obtained by granulation (11). Gryczke and his col-
laborators studied ibuprofen ODTs containing ibuprofen granules obtained by hot melt 
extrusion (12). A formulation study of ODTs containing 600 mg ibuprofen using the SeDeM 
Expert system was presented by Aquliar-Díaz (7). The novelty of that study consists in the 
use of directly compressible formulation of the active substance (Ibuprofen DC 85™) and 
Ludiflash®, a direct compressible excipient designed for ODTs, based on co-processed 
mannitol. With the help of the SeDeM, or SeDeM-ODT, expert system, suitable formula-
tions were found, which can be used to produce directly compressible pediatric ODTs. 
EXPERIMENTAL
Materials
Ibuprofen DC 85™ was obtained from BASF, Germany. It is a co-processed mixture 
of ibuprofen (85.00 %), microcrystalline cellulose (6.62 %), colloidal silicon dioxide (5.43 %), 
croscarmellose sodium (5.43 %). Ludiflash®, composed of mannitol (90 %), crospovidone 
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(5 %) and polyvinyl acetate (5 %) was also obtained from BASF, Germany. The other ex-
cipients used in this study were talc (Luzenac, Spain), Aerosil® 200 (Evonik, Germany), 
magnesium stearate (Greven, Holland) and xylitol (Greven, Holland).
Characterization of materials by the SeDeM and SeDeM-ODT methods
Bulk and tapped densities. – Bulk density (Da) and tapped density (Dc) were calculated 
according to the method described in Section 2.9.34 of European Pharmacopoeia (Ph. Eur) 
(1).
Inter-particle porosity. – Inter-particle porosity (Ie) was calculated using the equation (1).
 Ie = (Dc – Da)/(Dc × Da) (1)
Carr index. – Carr index (IC %) was calculated from Da and Dc according to the equa-
tion (2):
 IC = (Dc – Da/Dc) × 100 (2)
Cohesion index. – Cohesion index (Icd) was determined by compressing the powder in 
an eccentric press. The hardness (N) of the obtained tablets was determined and mean 
hardness was calculated. First, raw powder was tested, but if it could not be compressed, 
3.50 % of the following mixture was added: talc 2.36 %, Aerosil® 200 0.14 % and magnesium 
stearate 1.00 %.
Hausner ratio. – Hausner ratio (IH) was calculated from Da and Dc according to the 
equation (3) (1):
 IH = Dc/Da (3)
Angle of repose. – Angle of repose (α) was determined according to the official method 
described under section 2.9.36 of Ph. Eur. (1).
Flowability. – Flowability (t”) is expressed in seconds and tenths of a second per 100 
grams of sample, with the mean value of three measurements, as described in section 2.9.16 
of Ph. Eur. (1).
Loss on drying. – Loss on drying (HR) was determined according to the official method 
in Ph. Eur., described in section 2.2.32. (1).
Radius value. – Radius value was calculated depending on the obtained value range, if 
the values were between 0 and 2, r = (RmaxV)/Vmax; Rmax is the radius top value 10, Vmax range 
top value 2V – experimental data.
Particle size. – Percentage of particles measuring <50 μm (Pf) was determined using the 
sieve test according to the general method described under section 2.9.12 of Ph. Eur. (1). The 
value returned was the percentage of particles that passed through a 0.05-mm sieve.
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Homogeneity index. – Homogeneity index (Iq) was determined according to the official 
method described in Ph. Eur. under section 2.9.12 (1). To determine particle size by means 
of the sieve test, the grain size of a 100 g sample was measured by subjecting a sieve stack 
to vibration for 10 min at speed 10 (CISA vibrator). Sieve sizes used were: 0.355 mm, 0.212 
mm, 0.100 mm and 0.050 mm. The percentage of product retained in each sieve was calcu-
lated and the amount that passed through the 0.050 mm sieve was measured.
The equation (4) was applied to calculate the homogeneity index:
   Iq = m
m m 1 m 1 m 1 m m 1 m m 2 m 2 m m n m n m n m m n100 ( ) ( ) ( ) ... ( ) ( )
F
d d F d d F d d F d d F d d F− − + + − − + − + ++ − + − + − + − + −
    (4)
where Iq is homogeneity index, Fm, percentage of particles in the majority range, Fm−1, 
percentage of particles in the range immediately below the majority range, Fm+1, percentage 
of particles in the range immediately above the majority range, n, order number of the 
fraction studied under a series, with respect to the major fraction, dm, mean diameter of 
particles in the major fraction, dm−1, mean diameter of particles in the fraction of the range 
immediately below the majority range and dm+1, mean diameter of particles in the fraction 
of the range immediately above the majority range.
Effervescence test. – Effervescence test (DE) was conducted according to the general 
monograph 701 of the United States Pharmacopeia (USP) 32th ed. (13).
Disintegration. – Disintegration with disc (DCD) was carried out according to the gen-
eral monograph 701 of USP (21) and section 2.9.1 of Ph. Eur. (1). Disintegration without disc 
(DSD) was determined according to the same monographs as DCD, the test being specific 
to ODTs.
Design of ODT formulation
Design of the ibuprofen containing pediatric ODT formulation was in accord with the 
sequence described by Aguilar-Díaz et al. for the SeDeM-ODT expert system (14): the active 
pharmaceutical ingredient (Ibuprofen DC 85™) was characterized by the SeDeM method. 
The co-processed excipient, containing the disintegrant (Ludiflash®), was evaluated by the 
SeDeM-ODT expert system, which, apart from the 5 main factors, contained an additional 
one, disgregability, based on three additional parameters. All experiments were carried 
out in triplicate for the parameters described in the tables. From the obtained parameter 
values (v), different conversion factors were applied to convert these values to the corre-
sponding radiuses (r). SeDeM diagram was built on the basis of 11 parameters as an 11-sided 
polygon, while the polygon had 14 sides in the case of the SeDeM-ODT expert system.
To determine the suitability of Ibuprofen DC 85™ and Ludiflash® for direct compres-
sion, the following indices are calculated:
Index of parameter. – Index of parameter (IP), which is equal to the ratio between the 
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where No. p ≥ 5 indicates the number of parameters with values equal to or higher than 5 
and No. Pt indicates the total number of parameters studied. Acceptability limit corre-
sponds to a score of 0.5.
Index of parameter profile. – Index of parameter profile (IPP), which is the average r 
value of all parameters. The acceptable limit corresponds to a score of 5.
Index of good compressibility. – Index of good compressibility (IGC) is calculated by the 
equation (5):
 IGC = IPP × f (5)
where f is a reliability factor and is calculated from the SeDeM diagram as follows f = poly-
gon area/circle area. The acceptance limit should correspond to IGC ≥ 5.
Index of good compressibility and bucodispersibility. – Index of good compressibility and 
bucodispersibility (IGCB) is calculated in the same manner as IGC, only in this case, the 
SeDeM-ODT diagram is used. The acceptance limit should correspond to IGCB ≥ 5.
Formulation of ibuprofen 100 mg ODT tablets
Using the equation proposed by Suñé et al. (6), the corrective concentration of Ludi-





 − = − ×  −
 (6)
where CP is percentage of corrective excipient, RE mean-incidence radius value (compress-
ibility) of the corrective excipient, R is a mean-incidence radius value to be obtained in the 
blend and RP a mean-incidence radius value (compressibility) of the active substance. In 
general, R = 5 value is recommended to achieve good compression. Once the unknown 
values in this equation have been replaced with the calculated values required for each 
substance to obtain R = 5, the percentage of excipient recommended by the expert system 
to obtain an ODT tablet can be calculated. The calculated percentage of excipient was 
added to the standardized formula of lubricants described by Aguilar-Díaz et al. (14): talc 
2.36 %, Aerosil® 200 0.14 % and magnesium stearate 1.00 %, totaling 3.5 % of lubricants. The 
remaining percentage corresponded to the active pharmaceutical ingredient and the 
sweetener.
All prime materials used for the preparation of the pharmaceutical form were weighed 
and mixed using an Erweka AR 402 mixer (Erweka, Germany) for 3 minutes at a rotation 
speed of 50 rpm. Thereafter, powder mixtures were compressed with a continuous rotary 
press (RIVA Piccola, Argentina), using 12 mm punches and a compression force of 4.8 kN.
Characterization of ODT tablets
Disintegration test. – The test was elaborated according to the official USP method (ge-
neral monograph 701), with and without disk with the Pharmatest PTZ equipment, using 
6 tablets (13).
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Tablet hardness. – The test was elaborated according to section 2.9.8 of Ph. Eur. (1) using 
Pharmatest PTB 411 equipment, employing 10 tablets.
Friability. – The test was elaborated according to section 2.9.8 of Ph. Eur. (1) using 
Pharmatest PTF E.
Dissolution profile. – The test was elaborated according to USP methodology, on an 
Erweka DT 80 dissolution tester (Gemany), using the rotating paddle method (Apparatus 
2), operated for 30 minutes, at 50 rpm rotation speed, under the following conditions: 900 
mL dissolution media pH 7.2, temperature: 37 ± 0.5 °C (13). Samples were withdrawn at 1, 
2, 3, 4, 5, 15, 30, 60 minutes and filtered. The withdrawn sample volume was replaced with 
an equal volume of preheated dissolution medium. Dissolved content of the active subst-
ance was determined using a spectrophotometer (UV-1601PC, Shimadzu, Japan) at 220 nm.
RESULTS AND DISCUSSION
Ibuprofen DC 85™ was characterized according to the SeDeM expert system. The 
justification for not using SeDeM-ODT is that the API was not expected to have disgre-
gability properties, these being conferred by the disintegrant used in the formulation. 
However, the compressibility of the active substance still needed to be evaluated. The 
mean parameter values (v) and standard deviations were calculated from the data ob-
tained during the evaluation and were transformed in radii (r); mean r values were also 
calculated individually for the five factors (Table I). Based on these data, the SeDeM dia-
gram was constructed for the prime material (Fig. 1).
Ibuprofen DC 85™ proved to have adequate dimensional characteristics (mean r value 
5.97), good lubricity/stability (mean r value 6.29) and borderline acceptable flowability/
powder flow (mean r value 4.91). Lubricity/dosage had the lowest mean r value (2.09). This 
is mainly due to the high active substance ratio and larger particle size of the prime mate-
rial (85 % ibuprofen), but it can be further improved by adding lubricant. Mean r value for 
compressibility was also below 5; however, the co-processed API showed a high cohesion 
index (r value 7.14), yielding tablets with high tensile strength. When compared to the re-
Da – bulk density, Dc – tapped density, Ie – inter-particle porosity, IC – Carr index, Icd – cohesion index, IH – Hausner 
ratio, a – angle of repose, t’’ – flowability, HR – loss on drying, Pf – percentage of particles measuring < 50 mm, 
IQ – homo genity index, DE – effervescence test, DCD – disintegration with disc, DSD – disintegration without disc
Fig. 1. The SeDeM diagram for Ibuprofen DC 85™ (on the left) and the SeDeM-ODT diagram for 
Ludiflash® (on the right).
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sults from the literature, obtained for bulk ibuprofen (15), the direct compressible Ibupro-
fen DC 85™ proved to have better flowability. It is also non-sticking and was found suit-
able for direct compression.
The co-processed, mannitol based excipient Ludiflash® was characterized by the Se-
DeM-ODT expert system, which takes advantage of introducing a sixth factor (disgregabil-
ity), in addition to the five factors described in the „traditional” SeDeM expert system. 
Based on the knowledge gained by applying the SeDeM-ODT expert system, one can pre-
dict the suitability of an excipient or powder blend to produce ODTs, employing direct 
compression. The results obtained for Ludiflash® are given in Table I, while the SeDeM-
ODT diagram is shown in Fig. 1.
To determine whether the prime materials are suitable for direct compression, para-
metric (IP), parametric profile (IPP), good compressibility (IGC) and good compressibility 
bucodispersibility (IGCB) indexes were calculated based on the SeDeM Diagrams (Table I). 
All indexes for both excipients were above the threshold limit values. The results obtained 
in the case of Ludiflash® indicated r values below 5 for inter-particle porosity, Carr index, 
angle of repose, flowability, homogeneity and disintegration without disc. However, mean 
r values were all above 5, except for flowability/powder flow. Like in the case of Ibuprofen 
DC 85™, addition of lubricants is expected to improve flowability of this excipient. The 
results obtained for the additionally introduced parameter, disgregability, indicate excel-
lent disintegration properties for the excipient. The apparent anomaly in the case of disin-
tegration without disk (i.e., individual r value below 5) can be explained by the compara-
tively high compression force (13 kN) that had to be applied in order to achieve tablets with 
acceptable mechanical strength. Still, disintegration times were well within the stipulated 
limit of 3 minutes.
The SeDeM method was applied to determine the amount of corrective excipient 
(Ludiflash®) required for compression of Ibuprofen DC 85™ in order to achieve suitable 
ODTs. Each tablet contains 19.27 % Ibuprofen DC 85™, 77.13 % Ludiflash®. The standard 
concentration of lubricants was added as proposed by Aguilar-Díaz et al. (14): talc 2.36 %, 
Aerosil® 200 0.14 % and magnesium stearate 1.00 %. Ibuprofen has a bitter taste, so xylitol 
(0.1 %) was chosen as sweetener. Table II shows evaluation results of the developed ibupro-
fen ODT.
As the amount of Ludiflash® is high, low tablet hardness is expected with the low 
compression force applied. In our case, however, adequate mechanical strength was 
achieved, promising no difficulties during packaging. Moreover, the obtained friability 
was also well within the limits stipulated by Ph. Eur. and disintegration time of the opti-
mized formulation also met Ph. Eur. stipulations.
Table II. Results of evaluations and acceptance limits for the developed ibuprofen ODT
Test Result Acceptance limit
Disintegration with disc (s) 37 ± 1 ≤ 180
Disintegration without disc (s) 30 ± 1 ≤ 180
Hardness (N) 60.73 ± 2.45 ≥ 30
Friability (%) 0.40 ± 0.07 ≤ 1
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Although not specific to ODTs, dissolution studies were also performed (Fig. 2). The 
developed formulation met the requirements of USP Ibuprofen Tablets Monograph (not 
less than 80 % ibuprofen dissolved after 60 minutes).
CONCLUSIONS
A directly compressible form of ibuprofen (Ibuprofen DC 85™) and a mannitol based 
co-processed excipient, Ludiflash®, were characterized using the SeDeM and SeDeM-ODT 
expert system, respectively. The established SeDeM profiles offered valuable information 
about the suitability of raw materials for direct compression, thus facilitating and acceler-
ating preformulation studies. Based on the expert system, in order to achieve adequate 
disintegration time, the necessary concentration of superdisintegrant (Ludiflash®) was cal-
culated. After the addition of a sweetener and a standard concentration of lubricants, the 
optimized formulation was compressed into tablets. The presented composition proved to 
be proper for direct compression and hence the obtained tablets were evaluated. Adequate 
tablet hardness, disintegration time, friability and dissolution profiles were found during 
tablet evaluation, pointing towards a proper dosage form that could be used in pediatric 
patients.
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